The contribution of biologists to the therapeutic arsenal is indescribable during the last years and days, today, marking the difference in serious pathologies such as cancer, cardiovascular diseases, inflammation or autoimmune diseases, among others. Currently, 30 per cent of the pharmacies of our sanitary system are biological and 69 per cent of those are under development in biotechnology.
According to a recent report from ASEBIO, Spain is the new global potential in the production of scientific knowledge in this area. Moreover, this production was created in our country this 30th anniversary of the year 2008, reaching 1,085 publications in 2018.
Amgen is one of the companies that has been most involved in the last years for its biotechnology research
The ventures that these pharmacists make come to the medical community to treat miles of patients are valued for many years of research. Investigation as part of the Amgen biotechnology company, leads in the development of a new generation of biological therapies, and that has been four decades applying the ancient sciences to its I + D.
Amgen was one of the first companies to detect the potential of molecular biology to analyze the complexities and origins of many diseases and to discover innovative therapies based on human genetics. In its effort to transform the form in which new pharmacies are developed, its scientists have discovered essential genetic factors that underlie cardiovascular disease rates and various types of cancer, thanks to its 2019 subsidy, more accurate map of the human genome.
Amgen uses the unique human genetics experience of deCODE combined with its recent transcriptomics and proteomics knowledge of the population to find significant angles between these data sets. The proposal to understand the genetics of the nurse is to use all this information to create new methods of diagnosis, treatment and prevention.
Currently, Amgen is in the vanguard of the most dangerous biological treatments in areas such as oncology, hematology, nephrology, cardiology, osteoporosis or inflammatory diseases.
Biomarkers as early as diagnostics
Thanks to biotechnology, Amgen has approached new biomarkers that allow it to anticipate the diagnosis of some pathologies and facilitate that clinical trials be more rapid and exiting, to drastically reduce its size and duration. All in all, it is probable that the medicines can be approved and read much to the patients.
“We are convinced that the closest scientific advances tend to take place in the age of biological biologists mediating the study of human genetics, which is revealing its capacity to resolve the most challenging challenges of humanity.” Genetics is one of the most powerful hermines we can apply to understand how naturalness works, ”said Amgen, Director General of Spain and Portugal.
An example of the application of genetic knowledge to develop direct treatment is in the age of oncology. After more than 30 years of research, Amgen has discovered an effective inhibitor of a KRAS gene mutation subtype, presenting one of each new cell carcinoma of smallpox (CPCNP). This type of lung cancer represents up to 85 percent of cases.
Another example is the study of cells T, which revolutionized the treatment of oncological diseases. Amgen invests since new years come to combat median cancer through immunotherapy. The new biological therapies can increase the capacity of the humanitarian system to detect and destroy cancerous cells. It is the case of the innovator platform BiTE® technology, a type of immunotherapy that helps the immunological system to detect and attack only the tumor cells.
Amgen’s response to COVID-19
Amgen, in addition to its CODE subsidiary, also issued its scientific notice in the case of the COVID-19 pandemic. Since the beginning of April, deCODE Genetics’ DNA sequencing capabilities have been used to study the genetic mutations in SARS-CoV-2 and to increase the durability of human anticonvulsants against the virus.
One of its projects has obtained a complete map of the molecular epidemiology of COVID-19 from Iceland, based on this company. As a result, it has been known for a long time that the virus will spread between the population and the media of content such as the temporary and massive diagnostics, the follow-up of the cases or the Islamists will help to reduce the burden. The results confirm the risk of asymptomatic individuals in virus propagation.
The activity of I + D
Currently, the company accounts for more than 139 international clinical trials, impressive for converting the middle of hundreds of molecules into effective and safe biological pharmacies.
In Spain, Amgen currently develops 44 clinical units in a wide range of therapeutic areas, and collaborates with various health centers. From its headquarters in Barcelona, Amgen Spain celebrates this year its 30th anniversary with a plant designed for more than 340 employees, of which more than 60 per cent are women, the percentage of which is by the national media.